Pharma Ad Compliance Trends 2025

Pharmaceutical advertising in the GCC, especially in the UAE, has undergone major regulatory changes in 2025 to ensure higher compliance standards. Key updates include:

• Centralisation in the UAE: The Emirates Drug Establishment (EDE) replaced MOHAP as the primary regulator on 2 January 2025, managing all pharmaceutical advertising, product approvals, and pharmacovigilance.
• Stricter Advertising Rules: Absolute claims like "100% safe" or "miraculous" are banned. All promotional content must align with approved product uses and be backed by scientific evidence.
• Digital Advertising Oversight: Social media promotions now require specific licences (AED 1,000/month or AED 3,000/year). Violations, such as unapproved claims, can lead to fines up to AED 1,000,000 or imprisonment.
• GCC-Wide Coordination: Other GCC countries, like Saudi Arabia, are also tightening regulations, focusing on pre-approvals and accurate messaging.

The changes aim to safeguard public health by ensuring accurate, evidence-based advertising while introducing advanced tools like AI for monitoring compliance.

GCC PV Training 2025 - Day 2 | Session 5 - Updates On UAE PV Guidelines

Regulatory Changes and Advertising Rules Across GCC

Recent updates to advertising regulations across the GCC, building on reforms planned for 2024–2025, are tightening standards and reshaping how pharmaceutical promotions are managed.

UAE: Federal Decree-Law No. 38 of 2024 and Emirates Drug Establishment

In the UAE, the Emirates Drug Establishment (EDE) now oversees all pharmaceutical advertising under the newly introduced Federal Decree-Law No. 38 of 2024. This means that any promotional material for medical products must first receive EDE approval. Advertisements must strictly adhere to the details outlined in the Marketing Approval annex, which includes essential information like composition, uses, dosages, and potential side effects. By centralising this process, enforcement has become more streamlined.

Article 110 of the law sets additional responsibilities for marketing offices, requiring them to be managed by licensed professionals who monitor product circulation and ensure compliance with promotional guidelines. The law also extends its coverage to include more product categories under these stringent standards. For licence applications, the process has been simplified, with approvals typically issued within 1–3 days. Approved advertising materials must display their licence number prominently.

While the UAE has implemented significant regulatory changes, other GCC countries are following suit with similar measures.

Saudi Arabia: SFDA's Stricter Promotional Requirements

Saudi Arabia's Food and Drug Authority (SFDA) has introduced tougher rules for promotional content. It closely monitors digital advertising channels and bans exaggerated claims such as "miraculous", "guaranteed", or "100% success" in any promotional material. This reflects a broader push for more accurate and responsible advertising practices.

GCC-Wide Coordination and Standards

Across the GCC, efforts are underway to harmonise regulatory standards and definitions. This includes aligning product classifications and expanding the categories of regulated items, now covering biopharmaceuticals and advanced medical treatments like gene and cell therapies. Such changes are aimed at fostering cross-border regulatory alignment within the region.

Digital advertising and social media campaigns now require specific licences, adding another layer of oversight. Additionally, post-market surveillance has become more rigorous. Companies are now obligated to report adverse reactions within stricter timelines, which will influence how safety data is communicated throughout 2025. These updates not only standardise practices but also ensure a higher level of accountability across the region.

New Compliance Trends in Pharma Advertising

Pharmaceutical advertising in the GCC is undergoing a transformation, driven by three emerging trends: tighter evidence standards, advanced digital oversight, and a stronger focus on patient-centric messaging. These shifts build on recent regulatory updates and set the stage for the next phase of compliance across the region.

Evidence Requirements for Advertising Claims

Pharma companies are now required to ensure that all promotional content strictly aligns with approved product uses, backed by solid scientific evidence. In the UAE, the Health Advertisement Regulations explicitly ban absolute terms like "100%", "safe", "no side effects", "miraculous", or "guaranteed" in medical advertisements. Instead, advertisers must use relative claims, such as "helps to", which provide a more measured approach. Comparative advertising is allowed, but only if it is supported by scientific proof and avoids unfairly targeting competitors.

Digital Tracking and Post-Market Monitoring

With the introduction of the UAE's Federal Decree-Law No. 38 of 2024, a "National System for Tracking and Coding of Medical Products" has been implemented to monitor pharmaceutical distribution and safety in real time. This digital system enables authorities to quickly spot non-compliant content across digital platforms, offering a more efficient alternative to traditional monitoring methods. Many companies are now leveraging AI-driven tools to identify safety concerns and off-label promotions faster.

Recent statistics reveal that 63% of consumers expect brands to address harmful online content within an hour. This has pushed pharmaceutical companies to adopt continuous monitoring systems to meet these expectations.

"Adverse event detection is no longer a behind-the-scenes function. It's now a visible, strategic compliance priority for pharmaceutical brands." - Megan Ardis, Specialist Analyst, Resolver Corporate Intelligence

Additionally, electronic communications such as emails, SMS, or automated calls to healthcare professionals now require prior consent. Companies are also required to maintain mailing lists for potential product recall notifications.

Patient-Focused and Outcome-Based Communication

Pharmaceutical advertising is shifting away from traditional promotional messaging to focus on evidence-backed, patient-oriented communication. Patient Support Programmes (PSPs) must now include validated metrics covering medical outcomes, financial impact, and patient satisfaction. These metrics are reported periodically to health authorities, ensuring transparency and accountability.

This new framework also highlights the importance of personalised medicine. Any claims about outcomes must be backed by robust pharmacovigilance and post-market surveillance data. The goal is to align promotional content with real-world patient experiences rather than relying on theoretical benefits.

sbb-itb-058f46d

GCC Advertising Requirements Compared

Requirements by Country

The UAE has introduced a significant regulatory update. Starting from 2 January 2025, the Emirates Drug Establishment (EDE) will take over from MOHAP to manage advertising approvals, marketing authorisations, and market monitoring. This new framework comes with stricter penalties, including fines of up to AED 1,000,000 (around $270,000) for violations.

In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) has tightened its promotional regulations, placing greater emphasis on pre-approval processes and post-market surveillance.

Meanwhile, Qatar, Kuwait, Bahrain, and Oman continue to enforce their own regulatory systems, each with unique language policies and approval requirements. These differences highlight the varied regulatory environments across the GCC, as summarised in the comparison table below.

Compliance Comparison Table

The UAE's move to centralise regulation under the EDE signals a shift towards a more specialised approach, handling everything from pre-approvals to post-market monitoring and advertising compliance. This model could potentially inspire changes in regulatory systems across other GCC nations in the future.

Data-Driven Tools for GCC Pharma Advertising Compliance

In the Gulf Cooperation Council (GCC) region, data-driven tools have become essential for ensuring pharmaceutical advertising aligns with the latest regulatory requirements. These tools not only help companies stay compliant but also streamline the entire process, reducing risks and potential penalties.

How Data Analytics Supports Compliance

The introduction of Federal Decree-Law No. 38 of 2024 brought significant changes, including the creation of a National System for Tracking and Coding Medical Products and a centralised Medical Products Database. These systems empower data analytics platforms to validate product registration and traceability before launching campaigns.

Regulatory authorities now use real-time analytics to scan promotional content for prohibited terms like "magic", "miraculous", "100% safe", and "no side effects." These tools flag non-compliant language, helping brands avoid costly fines that can reach up to AED 1,000,000. Additionally, automated systems cross-check promotional materials against the Marketing Approval annex, ensuring all claims are supported by scientific evidence. This step is critical for meeting the standards set by regulatory bodies such as the Dubai Health Authority (DHA) and the Emirates Drug Establishment (EDE).

To further simplify compliance, companies can maintain digital repositories of peer-reviewed studies. These repositories make it easier to substantiate claims in comparative advertisements, ensuring adherence to strict guidelines.

AI-Based Personalisation and Automation

AI technology plays a key role in identifying and correcting non-compliant statements. For example, it flags absolute claims like "cures completely" or "permanent" and suggests alternatives such as "helps to" or "in most cases." AI also verifies the validity of advertising agency and influencer licences, which cost AED 1,000 per month or AED 3,000 per year. This automated pre-clearance process reduces delays in obtaining regulatory approvals while ensuring promotional materials meet legal standards.

When it comes to personalisation, AI must operate within strict data privacy boundaries. Personalised content is limited to non-prescription products, as advertising prescription-only medicines directly to consumers is prohibited. This ensures compliance with GCC advertising laws while tailoring messages for specific audiences.

Wick's Four Pillar Framework for Compliance

To complement technological advancements, Wick's Four Pillar Framework provides a structured approach to managing compliance within a unified digital ecosystem. This framework is designed to address GCC regulatory requirements through four key stages:

• Build & Fill: Ensures mandatory disclaimers are included in website content and digital ads, aligning with UAE's regulatory and cultural standards.
• Plan & Promote: Focuses on creating compliant advertising campaigns that meet local guidelines.
• Capture & Store: Supports pharmacovigilance by tracking adverse reactions and serious side effects, ensuring mandatory reporting to the Emirates Drug Establishment. This stage also uses data analytics to monitor campaign performance and adherence to approval timelines.
• Tailor & Automate: Utilises AI-driven personalisation to craft evidence-based messages, particularly for precision medicine models that consider genetic and lifestyle factors. This ensures that tailored communication remains within legal boundaries.

Conclusion

The pharmaceutical advertising landscape in the GCC has seen a dramatic shift, with stricter enforcement measures and penalties reaching up to AED 1,000,000. The introduction of the Advertiser Permit in July 2025 highlights the region's commitment to higher standards for digital content, ensuring that all promotional activities - whether paid or unpaid - adhere to stringent compliance rules.

Adapting to these changes requires leveraging data-driven tools to navigate the increasingly complex compliance landscape. With the one-year grace period provided by the new UAE law ending in January 2026, organisations must act swiftly to align their processes with the updated requirements.

As regulatory frameworks evolve, the focus on centralised oversight, digital transparency, and evidence-based communication will only grow stronger. Kuwait's 2025 regulations, mandating prior approval for digital content, further illustrate how GCC nations are harmonising their standards. For businesses, embedding compliance into their operational strategies is no longer optional - it’s a necessity to remain competitive in this rapidly changing environment.

FAQs

What are the consequences of violating the new UAE pharmaceutical advertising regulations?

Non-compliance with the updated pharmaceutical advertising regulations in the UAE carries serious consequences. Violators could be fined up to AED 1,000,000 and may also risk having their licence suspended or revoked.

Staying informed and fully compliant with these regulations is crucial for businesses to avoid both legal issues and financial setbacks.

How could AI-driven systems enhance compliance in GCC pharmaceutical advertising?

At present, there isn't any detailed information about AI-powered systems being utilised to oversee pharmaceutical advertising compliance within the GCC region. The primary discussions have centred around recent changes in advertising regulations, enforcement methods, and emerging compliance practices. Although AI holds promise for simplifying monitoring processes and ensuring alignment with local regulations, there’s no confirmed evidence of its application in this specific area so far.

What are the new digital advertising rules in the UAE for 2025?

In 2025, the UAE rolled out stricter rules for digital advertising, introducing the mandatory Mu’lin (Advertiser) Permit. This permit is required for brands and creators posting paid or promotional content on platforms such as Instagram, TikTok, and YouTube. Its purpose is to ensure adherence to disclosure rules, respect for local sensitivities, and high content quality standards. UAE citizens and residents can apply for the permit at no cost, with fees waived for three years. Visitors, however, must secure a short-term permit valid for three months.

On top of this, Federal Law No. 55 (2023) and Cabinet Resolutions No. 41 and 42 of 2025 mandate that anyone earning money from digital content must obtain a licence from the Media Regulatory Office (MRO). These regulations, which came into effect on 16-04-2025 and 29-05-2025, include a structured fee system and outline penalties for violations. Non-compliance can lead to fines or even account suspensions.

These measures aim to establish a consistent framework for digital advertising, ensuring all content - particularly health-related claims - aligns with the UAE’s regulatory and cultural expectations. All monetary amounts are referenced in UAE dirhams (AED), and dates follow the dd-MM-yyyy format.